Results of a Phase I Trial of Lenalidomide, Rituximab (R2) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma

TY - JOUR

T1 - Results of a Phase I Trial of Lenalidomide, Rituximab (R2) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma

AU - Mejia Garcia, Alex V.

AU - and institutional affiliations, Additional authors

N1 - INTRODUCTION: Lenalidomide and Rituximab (R2) is an effective frontline treatment regimen for patients (pts) with indolent B-cell lymphoma including follicular

PY - 2020

Y1 - 2020

UR - https://ashpublications.org/blood/article/136/Supplement%201/1/471749/Results-of-a-Phase-I-Trial-of-Lenalidomide

M3 - Article

VL - 136

JO - Blood

JF - Blood

ER -